Publication Name	World Journal of Clinical Pediatrics
Manuscript ID	100938
Country	India

Received	2024-09-02 04:19
Peer-Review Started	2024-09-05 05:49
To Make the First Decision
Return for Revision	2024-11-07 23:37
Revised	2024-11-14 10:11
Second Decision	2024-12-02 02:44
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-12-02 07:59
Articles in Press	2024-12-02 07:59
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2024-12-11 03:16
Publish the Manuscript Online	2024-12-20 07:07

ISSN	2219-2808 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Review
Article Title	Biologics in the management of pediatric inflammatory bowel disease: When and what to choose
Manuscript Source	Invited Manuscript
All Author List	Arghya Samanta and Anshu Srivastava
Funding Agency and Grant Number
Corresponding Author	Anshu Srivastava, MD, Professor, Department of Pediatric Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Rae Bareily Road, Lucknow 226014, Uttar Pradesh, India. avanianshu@yahoo.com
Key Words	Biologics; Children; Inflammatory bowel disease; Therapeutic drug monitoring; Dual biologic
Core Tip	Biologics have revolutionized the treatment of pediatric inflammatory bowel disease. The increasing number of biologics (anti-tumor necrosis factor alpha, anti-interleukin 12/23 agents, anti-alpha4beta7 integrin agents) and the arrival of small molecules (Janus kinase inhibitors, sphingosine 1-phosphate-inhibitors), have added to our therapeutic armamentarium. The ultimate objective of therapy is to achieve clinical remission and mucosal healing by providing “personalized therapy” keeping in mind the disease particulars, and selecting the therapy based on the efficacy, cost and safety of the biologics. In this review, we have summarized the recent available literature for guiding the pediatric gastroenterologist about the practical use of biologics and small molecules for children with inflammatory bowel disease.
Publish Date	2024-12-20 07:07
Citation	<p>Samanta A, Srivastava A. Biologics in the management of pediatric inflammatory bowel disease: When and what to choose. <i>World J Clin Pediatr</i> 2025; 14(1): 100938</p>
URL	https://www.wjgnet.com/2219-2808/full/v14/i1/100938.htm
DOI	https://dx.doi.org/10.5409/wjcp.v14.i1.100938

Full Article (PDF)	WJCP-14-100938-with-cover.pdf
Manuscript File	100938_Auto_Edited_021158.docx
Answering Reviewers	100938-answering-reviewers.pdf
Audio Core Tip	100938-audio.aac
Conflict-of-Interest Disclosure Form	100938-conflict-of-interest-statement.pdf
Copyright License Agreement	100938-copyright-assignment.pdf
Non-Native Speakers of English Editing Certificate	100938-non-native-speakers.pdf
Peer-review Report	100938-peer-reviews.pdf
Scientific Misconduct Check	100938-scientific-misconduct-check.png
Scientific Editor Work List	100938-scientific-editor-work-list.pdf
CrossCheck Report	100938-crosscheck-report.pdf